Curelator Inc.

Founded in Cambridge, Massachusetts, in 2013, Curelator develops clinical grade, personalized disease management tools for patients and clinicians. Currently, its main platform is N1-Headache, a unique patient engagement platform that delivers individualized, disease management tools for people with a history of migraine, allowing them to understand their migraine attack patterns, and what may affect these, in an individualized manner. Since its inception, Curelator has published dozens of papers and abstracts in major headache and migraine journals and at medical conferences. It has enrolled thousands of patients in clinical studies through its N1-Headache platform. Our mission is to improve healthcare by measuring patient reported outcomes and the factors that influence them and providing data to support optimisation of therapeutic pathways for each individual.